DRL launches Plermin for diabetic foot ulcers

EPP News Bureau - Hyderabad

Dr Reddy’s Laboratories (DRL) has launched Plermin - recombinant human Platelet Derived Growth Factor - rhPDGF- the first drug to be launched in India for the treatment of diabetic foot ulcers. The product will be available as a gel in 7.5 gm and 15 gm tubes.

Plermin represents the first and only therapeutic intervention for the treatment of diabetic foot ulcers, which is the leading cause of non-traumatic amputations in India. Majority of diabetic foot ulcers occur on account of neuropathy and it is estimated that approximately 40,000 patients undergo amputations each year.

Plermin is the first and only growth factor approved for managing this condition in India. It will enable significant reduction in the number of patients having to suffer the burden of foot or leg amputations in our country. rhPDGF is one of the most widely studied biological growth factors and has shown to promote formation of granulation tissue, thereby enhancing the rate and speed of healing in diabetic foot ulcers.

Several clinical studies have established its efficacy and safety in treating neuropathic diabetic foot ulcers. Satish Reddy, managing director and COO, Dr Reddy’s said, ‘‘The launch of Plermin marks a significant step for Dr Reddy’s in the area of foot care and reinforces our commitment to those patients who develop foot ulcers due to neuropathy. Plermin, the first rhPDGF in India, is the only growth factor that is widely studied and proven to offer faster healing of ulcers. The introduction of Plermin in India coincides with the theme of World Diabetes

Day and underlines the important role of foot care in reducing amputations’’.